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You may not be surprised to learn that many so-
called ‘autobiographies’ of celebrities such as 
David Beckham and Jackie Chan were not really 
autobiographies, but were written by another, 
uncredited author.1,2 Even the autobiography of the 
prolific writer Charles Darwin was partly ‘ghost-
written’ by his son, Francis.3 Ghost-writing is the act 
of authoring a book, manuscript, or other text that is 
officially credited to another person.4
 One perspective is that just because Beckham 
can bend a football and Jackie Chan appears to be able 
to survive falls with better dexterity than the average 
feline, it does not mean that they have a literary talent. 
Not that this should deter them from pleasing their 
fans with titbits from their personal lives. Ghost-
written autobiographies do not harm the people who 
read them. Ghost-written articles published in peer-
reviewed medical journals, however, may not be so 
innocuous and authors who lend their names to them 
should consider the possibility of plagiarism or even 
fraud. Why is this a problem in the medical literature 
and who engages in this practice? The most unethical 
scenario is when a pharmaceutical company employs 
a professional writing service to compile the results 
of clinical trials or scientific reviews (often the 
manuscript will be favourable towards the company 
paying for this service), then credits the writing to 
key opinion leaders (KOL), usually clinicians in the 
appropriate field, to lend credibility. The clinician 
‘author’ may never have seen the raw data from the 
trials in the manuscript that he or she is supposed 
to have authored and, in some cases, may not 
even have seen the completed manuscript prior to 
submission. The KOL will receive some reward in 
the form of money or a professional accolade. The 
company is then able to embed favourable marketing 
messages into the medical literature that is read by 
other clinicians and may influence their prescribing 
practice. Marketing of off-label or unlicensed use 
of drugs is illegal in most countries, including 
Hong Kong, but such use can be advocated in peer-
reviewed medical literature. 
 Although this practice has been known for 
decades, public attention was particularly drawn to 
it in 2009 when it was revealed, during a class-action 
against Wyeth’s (now owned by Pfizer) hormone 
replacement drug Prempro, that the pharmaceutical 
giant had employed a medical writing firm to develop 
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and implement a publication plan to promote 
hormone replacement therapy for a number of 
conditions. The writing firm ghost-authored four 
trial reports, 20 reviews, and more than 50 scientific 
abstracts, posters and journal supplements, all of 
which were published in peer-reviewed medical 
literature, and credited to various clinician KOL. 
When the results of the Women’s Health Initiative 
(WHI),5 a randomised trial involving 16 608 
women, revealed that despite its claims, hormone 
replacement therapy did not reduce the risk of 
coronary heart disease but instead increased the risk 
of stroke and breast cancer, the same medical writing 
firm systematically published reports to attack WHI, 
even going so far as to ghost-write responses to peer 
reviewers who questioned the continued citation of 
flawed studies advocating hormone replacement. 
 The process of scientific publishing, from 
inception to writing the manuscript, relies heavily 
on an honour system. Investigators report on trials, 
diseases, chemical analyses, and simulations but 
seldom are they requested to produce the raw data, 
spreadsheets, or other supporting material. When 
submitting work for publication, we are asked to 
disclose any conflicts of interest with little fear that 
anyone at the journal will investigate our declaration. 
It is obvious from the profuse infiltration of ghost-
written articles that this honour system can be easily 
abused. 
 Recently, there has been a surge in demand 
for the pharmaceutical industry to make their 
unpublished study raw data available.6-8 De-identified 
raw data may help our understanding of the various 
facets of large studies. Pharmaceutically sponsored 
or published results may well have significant 
implications for clinical practice but a certain degree 
of scepticism is healthy. Nonetheless, despite the 
growing awareness of the detrimental effects of 
ghost-written articles, their prevalence remains high. 
In a survey of corresponding authors in Annals of 
Internal Medicine, Journal of the American Medical 
Association, Lancet, Nature Medicine, New England 
Journal of Medicine, and PLOS Medicine published 
in 2008, 7.9% of authors reported that their articles 
included a ghost author.9 It is clear that more has to 
be done to curb this unsavoury practice. 
 Ghost-writers should not be confused with 
technical writers who work to polish manuscripts by 
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scientists or clinicians whose native language is not 
English. Writing articles to disseminate complicated 
medical or scientific data is not a simple task and 
there is a definite place in the medical literature 
for technical writers who can aid in the process of 
making this information more accessible to not 
only the public, but researchers who may not have 
specialised in that particular field. Ghost-written 
articles published in medical journals and paid for by 
commercial pharmaceutical/device companies are 
nothing more than advertisements masquerading as 
science. These intricately placed marketing messages 
are a blight to scientific writing and degrade the 
public’s trust in the medical profession. Attempts 
are being made by journal editors to crack down 
on ghost-writing. For example, senior editors in the 
medical journal PLOS Medicine suggest that journal 
policies should include enforceable sanctions such 
that any manuscript discovered to be written by 
people other than the named authors should be 
retracted and those authors banned from subsequent 
publication and their misconduct reported to their 
institutions.10 A well-conducted scientific and 
ethically performed study should have nothing to 
hide.
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